Back to results
US 2010/0144636 A1Published application
Peptides derived from ras-p21 and uses therefor
AssigneeThe Research Foundation of State University of New York
InventorsMatthew R. Pincus, Josef Michl, Victor Adler
Life of this patent
Estimating the term…
Abstract
A method of treating ras-transformed and ras-related cancer, including: administering to a plurality cells, including ras-transformed cancer cells and normal cells, a peptide material having a membrane resident peptide and a ras-p21 component, the membrane resident peptide attached to the carboxyl or amino terminal end of the ras-p21 component.
Claims25
A method of treating ras-transformed cancer, comprising:
- (i) providing a plurality of cells, said plurality of cells comprising:
- (A) ras-transformed cancer cells and normal cells;
- (B) cancer cells that either overexpress wild-type ras-p21 and/or jun-N-terminal kinase (JNK) and/or its target, jun and normal cells;
- (C) cancer cells lines that express oncogenic forms or that overexpress wild-type forms of any component like raf, MEK or MAPK that is essential to the oncogenic ras-p21 pathway;
- (D) normal cells;
- and
- (E) any combination of A, B, C, and D;
- and
- (ii) administering a peptide material having a membrane resident peptide and a ras-p21 component, said membrane resident peptide attached either to the carboxyl or amino terminal end of said ras-p21 component.
6 more elements
A method of treating ras-transformed cancer in a subject in need thereof, comprising the steps of:
- (i) providing a subject having a ras-transformed cancer, where such cancer is either a homozygous ras-transformed cancer exhibiting only oncogenic ras-p21 or heterozygous ras-p21 cancer exhibiting both oncogenic ras-p21 and wild-type ras-p21;
- (ii) administering to the subject a peptide material having a membrane resident peptide and a ras-p21 component, said membrane resident peptide attached to the carboxyl terminal or amino end of said ras-p21 component;
- and
- (iii) treating said ras-transformed cancer;
- wherein if said cancer is said homozygous oncogenic ras-transformed cancer, necrosing said cancer cells, and if said cancer is said heterozygous oncogenic ras-transformed cancer, phenotypically reverting said cancer cells.
2 more elements
A method of determining a ras-transformed cancer, comprising:
- (i) providing a sample of cells, said cells comprising cancer cells;
- (ii) administering to said cells an amount of an oncogenic ras-p21 blocking component;
- and
- (iii) observing a result thereof.
1 more element
Dependencies are inferred from the claim text.